Effect of Microporous Polysaccharide Particles in Patients Undergoing Mastectomy

Microporous polysaccharide particles (MPP), a hemostatic agent, were evaluated for post-operative outcomes. 190 patients were retrospectively reviewed. No difference was noted between those treated with and without MPP with regards to infection, seroma, or hematoma. Lymphovenous anastomosis (LVA) patients were more at risk of seroma and less likely to receive MPP. Consider utilizing MPP in this LVA population. Background: Microporous polysaccharide particles (MPP, proprietary name Arista AH), derived from purified plant starch, are used to augment hemostasis at surgery. The effect of MPP regarding short-term complications after mastectomy remains an area of ongoing investigation. Patients and Methods: A single-institution, retrospective chart review of patients undergoing unilateral mastectomy without reconstruction from January 2019 to 2021 was performed. Primary endpoints included antibiotic prescription, seroma or abscess drainage, readmission, wound dehiscence, and time to drain removal within 30 days of initial surgery. Wilcoxon rank sum test or Student t test was used for group comparisons for continuous variables; Chi-square test or Fisher exact test was used to evaluate the associations among categorical variables. Results: One hundred ninety patients were included; 119 received MPP and 71 did not. There was no difference in antibiotic prescription, infection drainage, hematoma, readmission, dehiscence, or time to drain removal with regards to MPP use. MPP treated patients were older (65.8 years vs. 59.1, P <.001) and had lower albumin levels (4.1 g/dL vs. 4.3, P =.025). Patients who underwent abscess drainage had higher body mass index ( mean 36.1 vs. 30.1 P =.036). Patients requiring seroma drainage were more likely to be diabetic (12.8% vs. 4%, P =.035) and to have been treated with lymphovenous anastomosis (LVA, 15.6% vs. 3.8%, P =.009). Patients who had LVA were significantly less likely to receive MPP when compared to other groups (3.1% vs. 74.7% P <.001). Conclusion: Consider utilizing MPP in patients at higher risk of seroma, such as those undergoing axillary surgery including LVA.

Automated summary

Microporous polysaccharide particles (MPP) were evaluated as a hemostatic agent for post-operative outcomes. The study found no significant difference in infection, seroma, or hematoma between patients treated with and without MPP. However, it was noted that patients undergoing lymphovenous anastomosis (LVA) were more at risk of seroma and less likely to receive MPP. Consideration should be given to utilizing MPP in this LVA population.